For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.
Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.
Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.
Other Financial or Material Support for Patents and Royalties from Elsevier.
Faculty/Planner
Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.
Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.
Presenter
Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.
Grant/Research Support from Sanofi.
Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Gui
Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Tr
Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhi
Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC
Create your
podcast in
minutes
It is Free
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PeerView Gastroenterology CME/CNE/CPE Audio Podcast